Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
The Lancet. Global Health|September 16, 2022
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trialDeborah Watson-Jones, John Changalucha, Hilary Whitworth, et al.
Plos Neglected Tropical Diseases|January 30, 2026
Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trialAnge-Marie D Kpetigo, Marie Alexandre, Aboubacar Camara, et al.
Plos Medicine|March 2, 2011
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysisNicola Low, Matthew F Chersich, Kurt Schmidlin, et al.
Vaccine|June 30, 2026
Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girlsHilary S Whitworth, Khalid B Beshir, Kathy J Baisley, et al.
The Lancet. Global Health|January 31, 2025
Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trialDeborah Watson-Jones, John Changalucha, Caroline Maxwell, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
Trials|January 24, 2021
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countriesMoses Badio, Edouard Lhomme, Mark Kieh, et al.
Ebiomedicine|April 26, 2023
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryChelsea McLean, Houreratou Barry, Mark Kieh, et al.
Vaccine|November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and UgandaEdward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
Vaccines|August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine RegimenDaniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
Pageof 15